Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions.
Flt3 ligand (FL) dramatically increases the number of immunostimulatory dendritic cells (DC) and their precursors in bone marrow (BM) and secondary lymphoid tissues. Herein we tested the ability of FL-mobilized donor hemopoietic cells to promote induction of skin graft tolerance across full MHC barriers. C57BL/10 (B10; H2(b), IE(-)) mice were given 10(8) spleen cells (SC) from normal or FL-treated, H-2-mismatched B10.D2 (H2(d), IE(+)) donors i.v. on day 0, 200 mg/kg i.p. cyclophosphamide on day 2, and 10(7) T cell-depleted BM cells from B10.D2 mice on day 3. B10.D2 skin grafting was performed on day 14. Indefinite allograft survival (100 days) was induced in recipients of FL-SC, but not in mice given normal SC. Tolerance was associated with blood macrochimerism and was confirmed by second-set skin grafting with donor skin 100 days after the first graft. In tolerant mice, peripheral donor-reactive T cells expressing TCR Vbeta11 were deleted selectively. Immunocompetence of tolerant FL-SC-treated mice was proven by rapid rejection of third-party skin grafts. To our knowledge this is the first report that mobilization of DC in donor cell infusions can be used to induce skin graft tolerance across MHC barriers, accompanied by specific deletion of donor-reactive T cells.
Department of Surgery and Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Medical Center, PA 15213, USA.
Masatoshi
M
Eto
Holger
H
Hackstein
Katsuhiko
K
Kaneko
Kikuo
K
Nomoto
Angus W
AW
Thomson
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D002469:Cell Separation; D002678:Chimera / Q000276:immunology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000637:transplantation; D005260:Female; D006085:Graft Survival / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D007274:Injections, Intraperitoneal; D008213:Lymphocyte Activation / Q000235:genetics; D008212:Lymphocyte Depletion; D008285:Major Histocompatibility Complex / Q000235:genetics / Q000276:immunology*; D008565:Membrane Proteins / Q000008:administration & dosage; D051379:Mice; D008810:Mice, Inbred C57BL; D016038:Skin Transplantation / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D023001:Transplantation Tolerance / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D014184:Transplantation, Homologous
D000276:Adjuvants, Immunologic; D008565:Membrane Proteins; C084881:flt3 ligand protein; D003520:Cyclophosphamide